Luye Life Sciences Group Opens R&D Center in Woburn, Massachusetts
07/17/2017
This global R&D facility, nine miles north of Boston, will collaborate with multiple business divisions of the Luye Life Sciences Group including Luye Pharma, Luye Medical, and Luye Diagnostics.
According to company officials, as an integral part of Luye Life Sciences Group's global R&D system, the newly-built Boston R&D Center will focus on international R&D collaboration.
In particular, joint efforts between Chinese and U.S. teams will accelerate the research and development of new drug candidates in key disease areas. The Boston R&D Center will act as an important center of excellence to internalize novel early-stage biopharmaceutical assets and disruptive drug delivery technologies.
"The opening of our Boston R&D Center marks another milestone in the Group's exploration of pharmaceuticals," said Dr. Youxin Li, Global R&D President of Luye Pharma Group. "Building on existing R&D platforms for the drug delivery system(DDS)and Mab biosimilars, Luye Pharma is moving towards next-generation biopharmaceutical products and intelligent drug products.”
“With Boston's leading position in the global biopharmaceutical industry, we look forward to laying a solid technical foundation through collaboration on new platforms and projects, to help ensure the sustainable pipeline development of Luye Life Sciences Group,” Dr. Li said.
Several biotechnology companies have already expressed their interest in working with the Boston R&D Center, tracking and analyzing a number of new early-stage drugs and technologies, company officials said. These projects will effectively promote and strengthen the R&D capabilities of Luye Life Sciences Group in key areas such as cancer, schizophrenia, depression, cardiovascular anomalies, and Parkinson's disease.
"R&D innovation is a core engine of our globalization strategy," said Rongbing Yang, President of Luye Pharma Group. "This Boston R&D Center allows us to further integrate our R&D resources across the world, speed up the introduction of new drugs to China, and bring our originally-developed drugs to overseas markets in order to benefit more patients worldwide."
According to Dianbo Liu, Chairman of Luye Life Sciences Group, the establishment of the Boston R&D Center is of great strategic importance. "Through this globalized platform, we look forward to building close connections with local universities, research institutes, the industry, and the financial sector," he said. "We believe these connections will allow us to seamlessly integrate our global R&D resources with those of new partners in order to streamline innovation and realize the commercialization of high-quality biopharmaceutical products.”
“We will continue to invest in this center, especially in terms of talent, capital, and operating processes. Ultimately, this will lead to the launch of many more innovative drugs as well as new products and technologies with real clinical value, thereby contributing to the health of all humankind,” Liu said.
Project Announcements
Republic Airways Holdings Plans Tuskegee, Alabama, Training Operations
04/18/2024
South Africa-Based Radel Plans Winston-Salem, North Carolina, Operations
04/18/2024
Firestone Industrial Products Expands Dyersburg, Tennessee, Operations
04/18/2024
Samsung Electronics Expands Taylor, Texas, Chip-Manufacturing Operations
04/18/2024
OMCO Solar Plans Huntsville, Alabama, Production Operations
04/18/2024
Martco-RoyOMartin Upgrades Allen Parish, Louisiana, Operations
04/18/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Making Hybrid More Human in 2024
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024